Dataset opportunity
Sterlingpharmasolutions — API可访问数据集机会
Sterlingpharmasolutions 持有的可 API 访问的大型数据集,可用作 RAG 和微调。
Score
71.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
82%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球制药制造中的人工智能市场在 2025 年的估值为 12.6 亿美元,预计复合年增长率为 29.45%(2026-2034 年)。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
API 可访问数据集
Modality
多模态
Sector
医疗保健
Volume
大型
Freshness
定期
Rarity
中等
Accessibility
部分
Legal
混合所有权 — 受限
Buyer persona
LLM 应用团队和企业搜索供应商
Sterling Pharma Solutions 持有一个多模态的API 可访问数据集,该数据集源自其合同开发和制造业务。它包含广泛的工业数据,包括工艺优化日志和制造记录,以及关键的监管文件、业务记录和专有的知识库。这种结构化和非结构化数据的丰富组合非常适合开发和支持RAG应用程序,以应对复杂的制药制造、质量和合规性查询。
该数据的价值体现在制药制造中的人工智能市场,该市场在 2025 年的估值为12.6 亿美元,预计将以29.45% 的复合年增长率增长。尽管存在数据所有权分割(客户知识产权 vs. Sterling 的工艺数据)、严格的 GMP/FDA 合规性以及客户 CDA 等访问复杂性,但该数据集的稀有性和深度提供了显著的竞争优势。对于希望在这个快速扩张、高价值领域进行创新的 AI 买家来说,这些高完整性的数据至关重要。⚠ 尽职调查(有价值的数据,可协商的访问权限):数据所有权是分割的:客户拥有分子知识产权,而 Sterling 拥有工艺优化和制造日志;严格的监管合规性(GMP/FDA)要求高数据完整性和受控访问;与全球制药客户的保密披露协议 (CDA) 限制了数据可移植性。· 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明了持有者拥有涵盖API 生命周期(从早期开发到规模化生产)的深入、多模态数据集。数据包括专有的工艺化学工作流程、数十年的工艺安全记录以及详细的分析方法。对于 AI 应用团队和企业搜索供应商而言,这是构建能够回答有关制药合同开发和制造(CDMO)运营的复杂查询的专业RAG系统的主要资产。在制药制造中的人工智能市场预计每年增长近 30% 的情况下,该数据集通过提供真实的运营数据,提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的 'API',医疗保健行业,2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
专有领域数据(开放会降低稀有度)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume100
12 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放(当前)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
适合 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI 买家需求异常强劲,这得益于高增长的制药制造中的人工智能市场,该市场正以 29.45% 的复合年增长率扩张。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility64
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility68
高难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength100
6 种证据类型,12 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License32
所有权=混合,许可=受限
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据胃口信号(0 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ 良好目标 — Sterling Pharma Solutions 是一个好目标,因为它是一家大型运营性 CDMO,从其 API 开发和制造的核心业务中生成专有数据,而它似乎并未将其作为单独的产品出售。问题:该公司比典型的中小型企业更大,员工人数从 1,000 多人到 1,350 人不等,这可能会影响其作为目标的分类;源描述“API 可访问数据集”中的术语“API”可能指的是“活性药物成分”,即公司的核心业务,而不是“应用程序”
- Deep Qualification90
⚠ 需要审查 — Sterling 是一家 CDMO,作为其核心业务的副产品,它会生成高价值的工艺和制造数据,但严格的客户保密和知识产权协议使得数据转售受到高度限制。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
API access
公开可访问的内容详细介绍了公司在API 制造和ADC 开发方面的核心服务,为 LLM 培训提供了基础业务背景和术语。
Industrial data
来自工艺化学工作流程和 30 年工艺安全计划的专有工业数据为构建制药制造中的预测模型提供了宝贵的材料和时间序列数据。
Downloads / exports
该公司提供可下载的公司资源,例如表格格式的工厂规格,这些规格提供了用于知识图谱构建的结构化数据点。
Knowledge base / docs
专有的知识库详细介绍了复杂的分析服务和方法,提供了高价值的技术文本,用于培训模型掌握制药质量和合规性。
business_records
内部业务记录,包括电子实验室笔记本和工艺表,代表了关于制药开发和质量控制的结构化数据的深层来源。
Regulatory records
关于质量源于设计 (QbD) 和 CMC 支持的专业监管文件为培训 AI 掌握新药申请提交的复杂要求提供了重要的文本。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Sterlingpharmasolutions API-Accessible — a Large api-accessible dataset (Multimodal modality) in the healthcare domain. Primary AI use-case: RAG. Market signal: Global AI in Pharma Manufacturing market was valued at $1.26 billion in 2025, with a projected CAGR of 29.45% (2026-2034).. Investment score 71.4/100 (confidence 0.82). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Escotobrokers — 法规记录数据集机会
View opportunity →出行Smartcustoms — 法规记录数据集机会
View opportunity →出行Frontierscs — 监管记录数据集机会
View opportunity →